Missense, nonsense and translationally silent mtuations can inactivate genes by altering the inclusion of mutant exons in messenger RNA, but their overall fraction among disease-causing exonic substitutions is unknown. Here, we have systematically tested missense and silent mutations deposited in the BRCA1 mutation databases of unclassified variants for their effects on exon inclusion in the mRNA experimentally. The introduction of 21 BRCA1 variants in two minigene systems revealed a single example of
INTRODUCTION
Single-nucleotide substitutions in exons are the most common type of mutations in human genetic disease [Cooper and Krawczak, 1993] . Missense (amino acid altering) and nonsense (stop codon creating) mutations form by far the largest group of mutations deposited in the Human Gene Mutation Database, accounting for ~56% of over 92,000 alterations recorded until May 2010 [Stenson et al., 2009] . However, nonsense, missense and also translationally silent mutations can inactivate genes by altering the inclusion of the mutant exon in mature transcripts Cooper and Mattox, 1997; Pagani et al., 2005; Valentine, 1998 ]. The most common outcome of these DNA alterations is exon skipping, which is associated with diminished expression of canonical mRNAs and is usually dramatic in severe phenotypes. Nevertheless, single-nucleotide variants in the coding region may induce more subtle changes in the relative expression of exon-lacking or exon-containing transcripts Cooper et al., 2009] . The exact proportion of such DNA alterations among disease-causing exonic substitutions is, however, unknown because RNA samples have not been examined in the majority of the cases and routine mutation screening has been largely based on DNA analysis.
Exonic substitutions often create or eliminate short elements that inhibit or activate exon inclusion, termed splicing silencers or enhancers, respectively. These motifs are abundantly present both in exons (ESSs, ESEs) and introns (ISSs, ISEs) and have been derived by computational and/or experimental approaches [Fairbrother et al., 2002; Liu et al., 2000; Wang et al., 2004; Zhang and Chasin, 2004] . However, the effect of exonic mutations and variants on splicing is strongly dependent on the sequence context and does not always correlate with in silico prediction [Goren et al., 2006; Lastella et al., 2006; Raponi et al., 2007; Skoko et al., 2008] . Although weak correlation with exon inclusion levels in minigenes was observed [Kralovicova and Vorechovsky, 2007] , the predictive value of ab initio computation tools is currently suboptimal.
Splicing defects resulting from exonic substitutions have been found in a growing number of disease genes, such as CFTR [Pagani et al., 2005; Raponi et al., 2007] , MLH1 [Auclair et al., 2006; Stella et al., 2001; Tournier et al., 2008] , ATM [Teraoka et al., 1999] , NF1 [Ars et al., 2000] , SMN2 [Lorson and Androphy, 2000] or BRCA1 . The latter gene is one of the two most important breast cancer susceptibility genes [King et al., 2003] , encoding a 1863 amino-acid protein involved in DNA damage repair and transcription regulation [Gowen et al., 1998 ]. Inheritance of a protein truncating mutation in this tumour suppressor gene is associated with a 40-80% lifetime risk of breast cancer [King et al., 2003] . Over 450 distinct BRCA1 missense mutations have been identified in patients with a strong family history of breast cancer, but the functional significance of many of these changes is unclear, with profound implications for genetic counseling.
In the present study, we have systematically tested 21 missense and silent mutations selected from the BRCA1 mutation databases of unclassified variants for their effects on exon inclusion in the mRNA using two minigene systems. We have identified a single exon-skipping mutation c.231>G>T. Systematic mutagenesis of a 12-nt segment surrounding this alteration showed that this alteration gave the highest exon skipping levels among 36 minigene substitutions and revealed a regular pattern of exon inclusion across this motif. Because this mutation was predicted by a combination of ESS and ESE elements, we have developed two online utilities termed EX-SKIP and HOT-SKIP that predict exon-skipping mutations ab initio and tested their performance using two datasets. These results reveal a new splicing regulatory element in BRCA1 exon 6 and facilitate identification of exonic alterations that result in exon exclusion from mature transcripts.
MATERIAL AND METHODS

Selection of BRCA1 variants
The Breast Cancer Information Core database (http://research.nhgri.nih.gov/bic/), an open-access on-line repository of mutations and polymorphisms of the inherited breast cancer genes, was searched to identify BRCA1 missense and silent mutations reported Table 1 ). The number of cases that sustained these mutations varied between 1 and 222. For further experimental study, we selected exons that were flanked by smaller introns that would allow us to construct unabridged splicing reporters that contained a high frequency of substitutions.
Construction of splicing reporters
OLIGO
® online software (http://www.oligo.net) was used to design PCR primers to amplify three-exon BRCA1 minigenes (Supplementary Table 2 ). Amplification was performed with anonymous genomic DNA, 1 μl of each primer (10 pmol/μl) and a mixture of 0.25 μl AmpliTaq Gold polymerase and 0.25 μl Pfu DNA polymerase. PCR products were visualized on agarose gels, DNA fragments were extracted using GENECLEAN ® and subcloned into pCR3.1 (Invitrogen). . Plasmid DNA was extracted using Wizard ® Plus SV Minipreps DNA Purification System (Promega). Site-directed mutagenesis was carried out using a megaprimer approach [Sarkar and Sommer, 1990] with mutagenic primers listed in Supplementary Table 3 .
Cell culture and transfections
HEK293 cells were grown in DMEM supplemented with 10% fetal calf serum and 2 mM L-glutamine in 6-well plates. One μg of each plasmid was transfected into 3x10 5 HEK293 cells per well in the serum-free medium containing Lipofectamine (Invitrogen) according to manufacturer's recommendations. Cells were grown for a total of 48 hrs post-transfection before harvesting for RNA extraction.
Analysis of spliced products
Total RNA was extracted using the Qiagen RNeasy Plus kit (Qiagen) according to the manufacturer's instructions. One μg of total RNA was reverse transcribed with the Reverse Transcription System (Promega) and the first strand of cDNA was amplified with vector primers PL3 and PL4 as described [Kralovicova et al., 2004] .
EX-SKIP and HOT-SKIP construction
Both tools were implemented as a common gateway interface script (written in Perl). Each utility perform a local search of the exonic sequence for putative ESEs/PESSs (PESEs/PESSs) [Zhang and Chasin, 2004] , FAS-ESSs [Wang et al., 2004] , RESCUEESEs [Fairbrother et al., 2002; Fairbrother et al., 2004] , neighbourhood inference [Stadler et al., 2006] and exon/intron identity elements (EIE/IIEs) [Zhang et al., 2008] The performance of HOT-SKIP was tested with a set of 37 previously reported mutations that resulted in exon skipping and genetic disease (Supplementary Table 4 ).
Each mutation was within the exon but outside the splice site consensus sequences, ie. the first and the last three exon positions. Set 2 consisted of exon 12 inclusion levels measured after transfection of the wild-type CFTR minigene and its 42 mutated versions, as published previously [Pagani et al., 2005; Pagani et al., 2003 ] (Supplementary Table   5 ).
RESULTS
Identification of a silent mutation in BRCA1 that induced exon skipping
A search of the Breast Cancer Information Core (BIC) database for diseaseassociated exonic substitutions identified a total of 487 alterations. For further investigation, we selected substitutions in BRCA1 exons 5, 6, 10 and 18 because they were flanked by relatively short introns and their length was also small (78, 89, 77 and 78 bp, respectively), thus facilitating DNA manipulation. We compiled a total of 38 nonsynonomous and 2 synonymous substitutions (Supplementary Table 3 ).
Splicing of the wild-type reporter construct containing exons 5-7 (Fig. 1A) produced a mixture of correctly spliced products and exon skipping. Examination of RNA products of reporters mutated at each exonic variant (Fig. 1B) revealed that the c.231G>T mutation significantly increased exon skipping as compared to the wild-type reporter ( Fig. 1C) , while the remaining variants in exon 6 did not produce any splicing defects.
The wild-type exon 9-11 minigene did not induce exon skipping, nevertheless we mutated this construct at each variant because it gave retention of the second minigene intron ( Fig. 2A-C) . None of the mutants produced exon skipping, but mutation c.5138T>C improved splicing of the second minigene intron, perhaps as a result of a removal of predicted ESS octamer AAATGGGT [Zhang and Chasin, 2004] and overlapping FAS-ESS hexamers TAGTTA, GTAGTT, GGTAGT and GGGTAG [Wang et al., 2004] from the wildtype construct. Minigenes containing exons 5 and 18 as middle minigene exons were either not informative or their cloning was unsuccessful.
Taken together, the introduction of 21 BRCA1 variants in two minigenes revealed a single (~5%) example of exon skipping upon c.231G>T mutation. This mutation was likely to markedly diminish expression of canonical BRCA1 transcripts in vivo and may have thus contributed to the development of breast cancer in the reported case.
Characterization of a silencer element in BRCA1 exon 6
The c.231G>T alteration may induce exon 6 skipping by creating a splicing silencer or eliminate an exonic enhancer. A systematic search for splicing regulatory elements revealed that this alteration increased the predicted ESS/ESE ratio about 70-fold (Table 1) . To identify residues that control exon 6 inclusion in this region and to systematically examine the contribution of each nucleotide, we mutated each position of a 12-nt region surrounding this mutation. Measurements of exon inclusion levels of the wild-type and 36 mutated constructs showed that the c.231G>T transversion gave the highest level of transcripts lacking exon 6 while only a few mutations reduced exon 6 skipping ( Fig. 3A) . This mutation creates a new TAG trinucleotide, which are highly enriched in splicing silencers [Wang et al., 2004; Vorechovsky, 2009] . In addition, exon skipping/inclusion levels across the mutated region showed a pattern of regular fluctuations that were only sporadically interrupted by more erratic changes, such as 224T or 231T, suggesting that the outcome of these changes can be predicted. As expected, the average exon skipping tended to be highest for substitutions that introduced uracil in the pre-mRNA (Fig. 3B ), consistent with a general enrichment of this nucleotide in splicing silencers [Wang et al., 2004; Vorechovsky, 2009] . Finally, although uracil is overrepresented in introns and in predicted splicing silencers, including FAS-ESSs [Wang et al., 2004] and PESSs [Zhang and Chasin, 2004] , it is worth noting that X>T substitutions did not increase exon skipping at each position (Fig. 3A) .
Correlation of the ESS/ESE profile and exon inclusion
To determine which of the previously determined ESSs or ESEs correlate best with exon inclusion levels, the number of RESCUE-ESEs [Fairbrother et al., 2002; Fairbrother et al., 2004] , FASS-ESSs [Wang et al., 2004] , PESEs/PESSs [Zhang and Chasin, 2004] , neighbourhood inference elements [Stadler et al., 2006] and EIE/IIEs [Zhang et al., 2008] was calculated for each segment. In addition, we employed the ESEfinder [Cartegni et al., 2003; Smith et al., 2006] to correlate exon inclusion levels with predicted scores of putative ESEs for SR proteins. The highest correlation with enhancers was observed for the score density of the improved consensus of serine/arginine-rich (SR) protein SF2/ASF (Fig. 3C, Supplementary Tables 6,7 ).
Together, ESEfinder predictions identified a total of 669 potential ESE motifs, with 34
potential ESEs within exons 5, 6, 10 and 18 (Supplementary Table 7 ), but putative ESEs for the remaining SR proteins did not significantly correlate with the exon inclusion.
A significant correlation was also found for EIEs (r=0.43), followed by a simple sum of all enhancers (r=0.37, Supplementary Table 8) . Conversely, the highest correlation between exon skipping and silencers was found for counts of FAS-ESSs (hex2 subset) (r=0.27), followed by trusted NI ESSs (r=0.25; Supplementary Table 8) .
Putative secondary structure
Of 36 minigene substitutions, the c.231G>T mutation gave the highest levels of exon skipping that were not matched by any other mutation. This could be due to an alteration of RNA secondary structure, which may convert the predicted single-stranded configuration into a base-paired structure and stabilize a terminal loop (Fig. 4A) . In an attempt to address this hypothesis, we introduced an additional destabilizing mutation at position 238. However, exon inclusion levels for this mutant at both the 231G and 231T background were higher than for the wild-type reporter construct (Fig. 4B) , which makes this explanation unlikely. Prediction of binding sequences using currently available online tools [Cartegni et al., 2003; Piva et al., 2009 ] has identified SR proteins SRp40 and SC35 as candidate factors, suggesting that the c.231G>T mutation could primarily alter protein binding (data not shown).
HOT-SKIP and EX-SKIP: online tools predicting exon skipping mutations
Because combination of independently derived splicing regulatory motifs have provided a better predictor of the c.231G>T mutation than individual elements (Table 1) ,
we have developed two online tools, termed EX-SKIP and HOT-SKIP, that compute the ESS/ESE profile using a single click of the mouse and, as we show below, facilitate identification of exon-skipping alterations.
EX-SKIP is a simple utility that compares the ESE/ESS profile of multiple short sequences, typically a wild-type and a mutated allele, to quickly determine which exonic variant has a higher chance to skip this exon. In contrast, HOT-SKIP systematically examines all possible substitutions at each exonic position, computes the ESS/ESE profile for each alteration and identifies 'hot' positions and substitutions that are most likely to skip this exon.
The input to both utilities is an exonic sequence (strictly in upper case) in the FASTA format flanked by short intronic sequences (lower case) on either side to account for adjacent motifs. Multiple FASTA format sequences are permitted up to a total length of 4,000 bp.
The output of EX-SKIP is a simple table indicating the number of each
ESSs/ESEs, their sum and ratio, which is followed by a short statement which of the submitted allele is more likely to skip the exon. By contrast, the HOT-SKIP output is a large table listing all possible point mutations at each exon position. 
Prediction of exon skipping mutations by HOT-SKIP
To illustrate the utility of this tool, we computed the ESS/ESE ratio for all possible point mutations at each exon position for 33 exons that sustained a total of 37 alterations, each resulting in exon skipping and genetic disease (Supplementary Table 4 ).
Mutations were ordered according to the ESS/ESE ratio for each exon. A subset of mutations that lacked any predicted ESSs was sorted according to the sum of ESEs.
Interestingly, we found that 20/37 (54%) of these mutations were in the first HOT-SKIP quartile, while 27/37 (73%) were in the first two quartiles (Fig. 5) . The bias in their distribution toward top HOT-SKIP positions was statistically significant (P=0.0001 and P<0.003, respectively, binomial tests). Interestingly, several of the 10 mutations that were in the third and fourth quartiles were located in the vicinity of top-ranking positions. For example, 10 mutations located up to 10 nt downstream of the disease-associated G>A substitution at position 37 of ADA exon 7 [Ozsahin et al., 1997] were ranked within the first 12 positions with the highest ESS/ESE ratios. Similarly, mutations introducing guanine at position 195-197 of the BRCA2 exon 18 were ranked by HOT-SKIP among the first 5 exon-skipping mutations, just 6 nt from the disease-causing substitution at position 189 [Fackenthal et al., 2002] . In cryptic exons, identical positions were in the top quartile if mutated to other nucleotides [Dear et al., 2006; Ishii et al., 2002] . These observations suggest that in a subset of cases, the ESS/ESE profile did not correctly predict mutations that are likely to reside within a shared secondary structure. This leads to prediction that the ESS/ESE profile may be more useful for less structured premRNAs. In addition, it may not perform well for mutations very close to natural splice sites. For example, two of the 10 'non-performing' mutations at position 7 in MLH1 exon 3 [McVety et al., 2006] and position 5 in GH1 exon 3 [Ryther et al., 2003 ]) were close to 3' splice sites and the 3'YAG consensus is likely to interfere with accurate prediction of exonic auxiliary sequences. In addition, these mutations were in exonic segments recognized by the auxiliary factor of U2 small nuclear ribonucleoprotein. The small subunit of this factor may bind up to 12 nt of the exon and has a preference for uridines [Wu et al., 1999] . Finally, because formation of cross-exon spliceosomal network is likely to be less complete for longer exons, we plotted exon length against the HOT-SKIP rank, but no correlation was found (r=0.027, P>0.05; Fig. 5 ).
We also compared previously published exon inclusion data for 42 mutations in CFTR exon 12 that were determined ex vivo [Pagani et al., 2005; Pagani et al., 2003 ]. We found a significant correlation of exon 12 inclusion with the ESS/ESE ratio (r=-0.28, P=0.03) as well as for the total number of ESSs (-0.35), but not for ESEs or any of the remaining individual elements, except for trusted NI-ESSs that gave the highest correlation coefficient (-0.40, P=0.004). Thus, these data suggest that the best prediction method may vary from exon to exon and highlight the versatility of HOT-SKIP to address this in detail in future studies.
DISCUSSION
This work has shown that (i) exonic point mutations that result in substantive exon skipping are infrequent in BRCA1 exons 6 and 10; (ii) prediction of exon-skipping mutations is facilitated by the ESS/ESS profile that takes into account independently derived elements and can now be easily determined online; (iii) exon 6 inclusion levels in the BRCA1 mRNA were not irregular but showed an undulating pattern across a systematically mutated segment that contained the newly identified and probably unstructured ESS.
We believe that the first conclusion is not limited to the two BRCA1 segments.
Although nonsense, missense and translationally silent mutations can inactivate genes by inducing the splicing machinery to skip the mutant exons, most mutations to illustrate this point were in fact in the splice-site consensus (see Table 1 in ).
Second, the low frequency of such mutations has been supported by independent screens of candidate exonic variants in other genes. For example, BRCA2 substitutions deposited in BIC and screened by RT-PCR and minigene assays did not show a single example of aberrant splicing [Whiley et al., 2010] . On the other hand, more systematic studies [Sanz et al., 2010] confirm previous findings [Pros et al., 2008; Teraoka et al., 1999] that in large genes with many introns up to a half of all disease gene mutations affect splicing, although only a few were in exons. For example, 2 of four exonic unclassified variants in BRCA2 showed aberrant splicing [Bonnet et al., 2008] . Thus, although the overall fraction of pathogenic exonic substitutions that cause aberrant splicing is likely to be relatively low, they should always be considered, particularly in exons weakly included in mRNAs, such as CFTR exon 12, where almost a third of all point mutations induced exon skipping in a minigene system [Pagani et al., 2005] (Supplemental Table 5 ).
Remarkably, the ESE/ESS profile correctly predicted a pathogenic mutation over a considerable distance from the exonic position ( Table 1 ) and suggested that a combination of independently derived elements has a better predictive and perhaps practical value. The new online tools are publicly available and should facilitate detection of DNA variants that alter splicing if carried out in conjunction with other tools that assess the strength of natural splice sites [Senapathy et al., 1990; Yeo and Burge, 2004] and branch points [Kol et al., 2005] . Similar algorithms have been recently applied to distinguish exon skipping and cryptic splice site activation ab initio [Divina et al., 2009] .
Interestingly, most minigene substitutions altered exon inclusion levels that ranged between 0.39 and 0.86% (Fig. 3A) . Disregarding the effect of the c.231G>T
mutation, these changes were minor and translated only to ~1.6-fold difference between maximum and minimum exon skipping. Remarkably, the pattern of these alterations was not irregular, raising a question of the underlying mechanism. Apart from alterations of cross-exon protein interactions and/or RNA secondary/tertiary structure, chromatin and histone modifications have been recently shown to influence splicing [Andersson et al., 2009; Gama-Carvalho et al., 1997; Kolasinska-Zwierz et al., 2009; Kornblihtt et al., 2009; Schor et al., 2009; Tilgner et al., 2009] . Exon marking and nucleosome occupancy between exons and introns also show only ~1.5-fold differences and nucleosome occupancy improved exon recognition only to a limited degree [Spies et al., 2009] .
Taken together, screening of 21 unclassified exonic variants in BRCA1 has identified a single case of exon skipping. Systematic mutagenesis surrounding the new ESS in BRCA1 exon 6 revealed only modest variations in exon inclusion for the majority of changes, supporting the view that exonic point mutations that result in pathogenic exon skipping are relatively infrequent. The newly developed online tools should facilitate detection of exonic alterations that reduce exon inclusion in mRNAs and represent the first step toward developing more sophisticated algorithms in the future. Figure 1 Identification of the BRCA1 missense mutation that induce exon skipping Legend: A, 5-7 minigene reporter construct. Exons are shown as boxes (numbered 5-7), introns as lines. Normal and aberrantly spliced products are shown as dotted lines above and below the pre-mRNA, respectively. Transposable elements in introns are schematically shown as grey (AluJb), white (3'end of L2) and black (MER104) rectangles; their orientation is denoted by arrowheads. Cloning primers are shown as grey arrows. B, exon 6 sequence (upper case) with flanking intronic sequences (lower case). Substitutions (bold) are shown above mutated residues (highlighted). c.231G>T substitution creates the TACTAG hexamer (underlined) predicted by FAS-ESS and also the CTAGAT splicing regulatory motif (highlighted in grey) predicted by a computational method based on the conservation of wobble positions the overabundance of sequence motifs between human and mouse orthologous exons [Goren et al., 2006] . C, RNA products of the BRCA1 5-7 minigene (schematically shown to the right) visualized by reverse-transcription PCR and separated by PAGE. Minigene mutations (top) correspond to panel B. Supplementary Table 4) . HOT-SKIP percentile was calculated as (a-4)*400/n, where n is exon length in nucleotides and a is the rank of the mutation among all possible exon substitutions as determined by sorting the ESS/ESE ratios.
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